- Home
- CLMT vs EXEL Comparison
CLMT vs EXEL Comparison
Compare CLMT & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLMT | EXEL |
|---|---|---|
| Founded | 1916 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 11.1B |
| IPO Year | 2006 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CLMT | EXEL |
|---|---|---|
| Price | $20.52 | $40.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 24 |
| Target Price | $20.45 | ★ $45.18 |
| AVG Volume (30 Days) | 550.5K | ★ 2.6M |
| Earning Date | 11-07-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | N/A | ★ 2.38 |
| Revenue | ★ $4,048,000,000.00 | $2,288,218,000.00 |
| Revenue This Year | $0.16 | $9.84 |
| Revenue Next Year | N/A | $11.92 |
| P/E Ratio | ★ N/A | $17.20 |
| Revenue Growth | N/A | ★ 9.93 |
| 52 Week Low | $7.68 | $31.90 |
| 52 Week High | $23.75 | $49.62 |
Technical Indicators
Market Signals| Indicator | CLMT | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 67.75 | 43.05 |
| Support Level | $19.17 | $43.00 |
| Resistance Level | $19.80 | $44.79 |
| Average True Range (ATR) | 0.53 | 1.15 |
| MACD | 0.13 | -0.45 |
| Stochastic Oscillator | 96.44 | 3.65 |
Price Performance
Historical ComparisonAbout CLMT Calumet Specialty Products Partners L.P.
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.